Delivery Order SPE2DB22D9353-SPE2DB25FX2EX
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $17,574.41 to DMS Pharmaceutical Group Inc. on August 11, 2025, for the supply of EXPAREL 266 mg/20 mL vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract at its Park Ridge facility with an ultimate completion date of September 2, 2025. This delivery order was issued without a set-aside designation, allowing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,107.10 to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This delivery order represents a firm fixed-price contract with an ultimate completion date of September 30, 2025, and will be fulfilled from the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The contract, awarded on September 17, 2025, carries a ceiling value of $15,063.78 and operates under a firm fixed-price structure with an ultimate completion date of October 8, 2025. This delivery order was issued without set-aside designation,...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The contract, valued at approximately $25.1K, carries an ultimate completion date of September 29, 2025, and was issued on September 8, 2025. This delivery order does not utilize a set-aside designation, allowing DMS Pharmaceutical Group...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, with a ceiling value of $20,085.04. The contract calls for the delivery of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials, a long-acting local anesthetic used in surgical and medical settings. The award carries no set-aside designation and is scheduled for ultimate completion...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,655.32 to DMS Pharmaceutical Group Inc. on September 19, 2025, for the supply of EXPAREL (133 mg/10 mL vial). This award represents a firm fixed-price delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.9 billion vehicle established to streamline pharmaceutical procurement for military health facilities. The order is scheduled for completion by October...
- The Defense Logistics Agency awarded a $25,106.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 31, 2025, for the supply of EXPAREL 266 mg/20 mL vials. This delivery order, which carries an ultimate completion date of August 21, 2025, represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million through November 2026. The award was made without set-aside designation, allowing DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a $50,212.60 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and was awarded on August 5, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The contract is a firm fixed-price delivery order with a ceiling value of $12,553.15 and an ultimate completion date of August 4, 2025. This award was made without a set-aside designation, and the place of performance is Park Ridge, Illinois. DMS Pharmaceutical Group is...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 27, 2025, for EXPAREL 266 mg/20 ml vials valued at $10,042.52. This firm fixed-price delivery order, which has a completion date of September 18, 2025, was issued without a set-aside designation. The award represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2EXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,106.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 17, 2025. The contract calls for delivery of EXPAREL 266 mg/20 ml vials and is structured as a firm fixed-price delivery order with an ultimate completion date of October 8, 2025. This award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its small business status. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.99 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products to support military healthcare facilities worldwide. EXPAREL (liposomal bupivacaine) is a long-acting local anesthetic used in surgical and perioperative pain management. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its established IDC to fulfill firm fixed-price delivery orders for medications, biologics, and medical consumables needed across Department of Defense healthcare sites globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.1k | 9/17/25 |